Copyright
©The Author(s) 2023.
World J Gastroenterol. Jul 14, 2023; 29(26): 4136-4155
Published online Jul 14, 2023. doi: 10.3748/wjg.v29.i26.4136
Published online Jul 14, 2023. doi: 10.3748/wjg.v29.i26.4136
Figure 3 Beneficial effects of Peroxisome proliferator-activated receptor agonist on islet remodelling.
Diet-induced obese mice exhibit enlarged pancreatic islets, with are prone to exhaustion in the long run due to glucolipotoxicity. Peroxisome proliferator-activated receptor α (PPARα) and partial PPARγ activation are promising targets to counter glucolipotoxicity, yielding islet preservation. Made with Biorender (www.biorender.com). PPARs: Peroxisome proliferator-activated receptors; GSIS: Glucose-stimulated insulin secretion; ER: Endoplasmic reticulum. Created by BioRender.
- Citation: Souza-Tavares H, Miranda CS, Vasques-Monteiro IML, Sandoval C, Santana-Oliveira DA, Silva-Veiga FM, Fernandes-da-Silva A, Souza-Mello V. Peroxisome proliferator-activated receptors as targets to treat metabolic diseases: Focus on the adipose tissue, liver, and pancreas. World J Gastroenterol 2023; 29(26): 4136-4155
- URL: https://www.wjgnet.com/1007-9327/full/v29/i26/4136.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i26.4136